1-4 of 4
Shifang Yang, PhD
Close
Sort by
Journal Articles

Transiently Elevated AST/LDH Are Associated with Clinical Response to Recombinant Circularly Permuted TRAIL (CPT) Plus Thalidomide in Patients with Relapsed and/or Refractory Multiple Myeloma

Wenming Chen, MD, Peng Wei, PhD, Shifang Yang, PhD, Xiangjun Zheng, Lugui Qiu, MD, Jian Hou, MD PhD, Xuejun Zhang, MD, Zhao Wang, Xiaoyan Ke, MD PhD, Ling Pan, MDPhD, Hongyan Pang, PhD
Journal: Blood
Blood (2014) 124 (21): 3478.
https://doi.org/10.1182/blood.V124.21.3478.3478
Published: 2014
Journal Articles

Phase Ib Study of Recombinant Circularly Permuted TRAIL (CPT) in Relapsed or Refractory multiple Myeloma Patients

Wenming Chen, MD, Lugui Qiu, MD, Jian Hou, MD, PhD, Xuejun Zhang, Xiaoyan Ke, MD, PhD, Zhao Wang, MD, PhD, Fang Zhou, Shifang Yang, PhD, Yaozhong Zhao, Yun Leng, Hao Xi, Fuxu Wang, Bing Zhu
Journal: Blood
Blood (2012) 120 (21): 1857.
https://doi.org/10.1182/blood.V120.21.1857.1857
Published: 2012
Journal Articles

Circularly Permuted TRAIL (CPT) combined with Thalidomide for the Treatment of Relapsed or Refractory Multiple Myeloma: An Open-Label, Multicenter Phase II Clinical Trial.

Wenming Chen, MD, Jian Hou, MD, PhD, Yaozhong Zhao, Lugui Qiu, MD, Xiaoyan Ke, MD, PhD, Zhao Wang, MD, PhD, Yun Leng, Hongmei Jing, Hao Xi, Xiangjun Zheng, Fuxu Wang, Bing Zhu, Shifang Yang, PhD
Journal: Blood
Blood (2012) 120 (21): 2958.
https://doi.org/10.1182/blood.V120.21.2958.2958
Published: 2012
Journal Articles

Recombinant Circularly Permuted TRAIL (CPT) for the Treatment of Relapsed or Refractory Multiple Myeloma: An Open-Label, Multicenter Phase II Clinical Trial

Wenming Chen, MD, Lugui Qiu, MD, Jian Hou, MD, PhD, Yaozhong Zhao, Ling Pan, Shifang Yang, PhD, Yun Leng, Hao Xi, Xuejun Zhang, Junsheng Cui, Na Wei
Journal: Blood
Blood (2012) 120 (21): 78.
https://doi.org/10.1182/blood.V120.21.78.78
Published: 2012